All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Impact of donor age and type in patients with AML undergoing allo-HSCT
|
A retrospective analysis compared transplant outcomes in patients with acute myeloid leukemia (AML) in first complete remission undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), with post-transplant cyclophosphamide (PTCy), from young (<30 years) haploidentical (haplo) donors vs old (≥35 years) mismatched unrelated donors (MMUD), and old haplo donors vs young MMUD.1 The analysis included 2,798 patients (young haplo, n = 1065; old MMUD, n = 147; old haplo, n = 1315; young MMUD, n = 271) from a dataset of the Acute Leukemia Working (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Results were published in Bone Marrow Transplantation by Nagler et al.1
|
| Key learnings: |
|
Results suggest that allo-HSCT from young haplo donors (median age, 27.8 years) is associated with a lower incidence of Grade II–IV acute graft-versus-host disease (aGvHD) at Day 180 compared with old MMUD (median age, 41.8 years; 22.6% vs 35.7%; hazard ratio [HR], 0.62; p = 0.007), without differences in other key outcomes, such as chronic GvHD, relapse incidence (RI), non-relapse mortality (NRM), leukemia-free survival (LFS), overall survival (OS), and GvHD-free and relapse-free survival (GRFS). |
|
Compared with older haplo donors (median age), patients transplanted with younger MMUD (median age) had a reduced risk of Grade II–IV aGvHD at Day 180 (24.3% vs 31%; HR, 0.69; p = 0.013) and a lower 2-year NRM rate (11.6% vs 22.4%; HR, 0.60; p = 0.022). RI, LFS, OS, and GRFS were similar between groups. |
|
The study highlights that donor age is a critical factor impacting transplant outcomes, and suggests that younger, alternative donors should be prioritized when selecting donors for allo-HSCT with PTCy in patients with AML. These findings also warrant further investigation in prospective age-focused studies. |
- Nagler A, Labopin M, Swoboda R, et al. Young (<35 years) haploidentical versus old (≥35 years) mismatched unrelated donors and vice versa for allogeneic stem cell transplantation with post-transplant cyclophosphamide in patients with acute myeloid leukemia in first remission: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2024. Online ahead of print. DOI: 10.1038/s41409-024-02400-5
Your opinion matters
3 votes - 63 days left ...
Related articles
Newsletter
Subscribe to get the best content related to GvHD delivered to your inbox